Stimulants vs Strattera (atomoxetine) for adult ADHD

For adult ADHD, the first big fork in the road is usually between a stimulant (an amphetamine or methylphenidate product) and a non-stimulant. Atomoxetine, sold for years as Strattera, is the non-stimulant with the longest record in adults. This page compares the stimulant class as a whole with atomoxetine, using FDA labels, two large network meta-analyses of adult trials and current guidelines, as of October 2026. A second non-stimulant, viloxazine (Qelbree), is compared with atomoxetine in Strattera vs Qelbree.

Side by side

The "how long it lasts" row for atomoxetine is a simplification: the Strattera label describes once-daily or twice-daily use but does not frame the drug in hours of coverage the way stimulant labels do.

What the research says in adults

• Cortese 2018, Lancet Psychiatry. Across 133 double-blind trials, in adults (clinician ratings at about 12 weeks), amphetamines, methylphenidate and atomoxetine all reduced symptoms more than placebo. In head-to-head comparisons in adults, amphetamines showed larger effects than atomoxetine. Atomoxetine and methylphenidate were less well tolerated than placebo in adults, and so were amphetamines.
• Ostinelli 2025, Lancet Psychiatry. In 113 adult trials, stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-reported and clinician-reported scales at 12 weeks. Stimulants were similar to placebo in acceptability (all-cause dropout), while atomoxetine had lower acceptability than placebo. The authors also found that ADHD medications did not improve quality of life in these trials and that long-term evidence is thin.

On average, then, stimulants show somewhat larger short-term effects, and atomoxetine is a real, evidence-based alternative rather than a weak substitute. Averages do not predict individual response. Does ADHD treatment work in adults? explains the numbers in more depth.

What guidelines say about when to use each

• NICE (UK), NG87. Offers lisdexamfetamine or methylphenidate first-line for adults, and atomoxetine if a person cannot tolerate those or has not responded to separate six-week trials of each. NICE also says people with ADHD and anxiety disorder, tic disorder or autism should be offered the same medication choices as others.
• American Family Physician (2024). Describes stimulants as first-line for adults and lists atomoxetine, viloxazine and bupropion as options for adults who cannot take stimulants or who have concurrent anxiety or depression.

Common reasons a prescriber and patient might lean toward atomoxetine include a history of substance misuse, stimulant side effects that did not settle, certain health conditions, or a preference to avoid a controlled substance. Reasons to lean toward a stimulant include the larger average effect and the ability to adjust day-to-day coverage. Stimulant vs non-stimulant ADHD medication covers these trade-offs across all options.

Misuse and controlled-substance status

All prescription stimulants carry the FDA boxed warning on abuse, misuse and addiction, added class-wide on May 11, 2023, and they are Schedule II drugs. The Strattera label states that atomoxetine "is not a controlled substance," and that in an abuse-potential study in adults it "was not associated with stimulant or euphoriant properties." See ADHD medication misuse and addiction risk.

Safety warnings that differ

• Atomoxetine: severe liver injury (stop and do not restart with jaundice or lab evidence of liver injury); urinary retention or hesitancy; contraindications for narrow angle glaucoma, pheochromocytoma and severe cardiovascular disease; higher levels in CYP2D6 poor metabolizers and with strong CYP2D6 inhibitors such as paroxetine and fluoxetine.
• Stimulants: abuse and misuse; for amphetamines, interactions with alkalinizing and acidifying agents; for methylphenidates, glaucoma, eye pressure and priapism warnings.
• Shared: increases in heart rate and blood pressure, psychiatric effects including new psychotic or manic symptoms, and contraindication with MAOIs.

Heart questions for both are covered in ADHD medication, heart health and blood pressure.

Day-to-day differences

Several stimulant labels advise against late-day doses because of insomnia, and some stimulant capsules (Adderall XR, Vyvanse) can be opened and sprinkled on food. Atomoxetine works differently in daily life: the label says its capsules are not intended to be opened because the contents irritate the eyes, and it advises caution with driving or operating machinery until a person knows whether atomoxetine makes them sleepy. For adults who are CYP2D6 poor metabolizers, the label notes higher exposure and lists side effects that were more frequent in that group.

What changes in New York and New Jersey

The legal gap is large. Stimulant prescriptions in both states follow Schedule II rules: no refills (10 NYCRR 80.67 in New York; N.J.A.C. 13:45H-7.9 in New Jersey), supply limits and monitoring-program checks, explained in New York's rules and New Jersey's rules. Atomoxetine is not a controlled substance, so none of those Schedule II limits apply to it. Shortages are also less of an issue: as of October 19, 2026, atomoxetine did not appear on the FDA's current shortage list, while several stimulants did.

Questions worth asking

• Is there a reason in my history to avoid a controlled substance?
• Do I take an antidepressant or other medicine that interacts with atomoxetine?
• Do I have liver disease, glaucoma or heart disease?
• How soon would we judge whether each option is working?
• If the first choice does not work, what comes next?

Talking it through with a prescriber

Dr. Shershow is a psychiatrist focused on adult ADHD and licensed in New York and New Jersey. He offers treatment planning and medication management when medication is appropriate. This page is general information, not advice to start, stop or switch any medication, and no single option is right for every adult.